MEMORIA CIENTIFICA 2023

Servicio de Dermatología Hospital Universitario San Cecilio

 

PUBLICACIONES

 

Dermatología General

 

1. Pegalajar-García MD, Mellado J, Ruiz-Villaverde R, Navarro-Triviño FJ.Erythematous Plaque in the Left Axillary Region: A diagnostic challenge where dermoscopy can help. Sultan Qaboos Univ Med J. 2023 Nov;23(4):560-561. doi:10.18295/squmj.5.2023.034. Epub 2023 Nov 30. PMID: 38090241; PMCID: PMC10712377.
2. Prados-Carmona A, Ruiz-Villaverde R, Navarro-Triviño FJ. Ist Roflumilast eine geeignete Alternative zur Behandlung des lichen planus? J Dtsch Dermatol Ges.2023 Dec;21(12):1554-1556. doi: 10.1111/ddg.15204_g. PMID: 38082528.
3. Prados-Carmona A, Prados-Carmona JJ, Ruiz-Villaverde R, Navarro-Triviño FJ.Multiple Minute Digitate Hyperkeratosis: 10 Jahre nach Caccettas Algorithmus.Fallbericht und narrative Übersicht. J Dtsch Dermatol Ges. 2023 Dec;21(12):1447-1455. doi: 10.1111/ddg.15186_g. PMID: 38082527.
4. Pereyra-Rodriguez JJ, Baldrich ES, Ruiz-Villaverde R, Torres EB, De la C Dobao P, Nart IF, Menéndez ÁF, Martin-Santiago A, Miquel JM, Silvestre JF, Armario-Hita JC. Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus. Acta Derm Venereol. 2023 Nov 20;103:adv12314. doi: 10.2340/actadv.v103.12314. PMID: 37982727; PMCID: PMC10680463.
5. Cebolla-Verdugo M, Cabrerizo-Carvajal A, Ruiz-Villaverde R. Dermatosis glútea senil [Senile gluteal dermatosis]. Semergen. 2023 Nov 17;50(3):102130. Spanish. doi: 10.1016/j.semerg.2023.102130. Epub ahead of print. PMID: 37980782.
6. Prados-Carmona A, Remón-Love A, Ruiz-Villaverde R. Black-purplish nodules on skin: a time-sensitive finding. J Dtsch Dermatol Ges. 2023 Nov 5. doi: 10.1111/ddg.15295. Epub ahead of print. PMID: 37926837.
7. Galván Casas C, Ruiz-Villaverde R, Prados-Carmona Á, Fernández Camporro Á, Angulo Menéndez AG, Álvarez-Buylla Puente MC, Pasquali P, Aguado Vázquez Á, Masferrer E, Rodríguez González L, Ruiz-Sánchez D, Caballero-Linares CF, Tejera- Vaquerizo A, Iglesias-Pena N, Fernández de Piérola S, Maldonado-Seral C, Armengot-Carbó M, Alonso-Naranjo L, Barros Tornay R, Solano Novo T, Fernández Tapia V, Martín-Gorgojo A, Adsuar Mas J, Parera Amer ME, Pérez Feal P, Taberner R, Utrera-Busquets M, Vicente Sánchez I, Palacio Aller L, Sánchez-Gutiérrez I, Usero-Bárcena T, Aldea Manrique B, Sánchez Velázquez A, Martínez García E, Grau- Pérez M, García-Doval I; CLINI-AEDV. [Translated article] Clinical and Epidemiological Characteristics of Patients Being Treated for Scabies in Spain: Opportunities for Improvement - A Multicenter Cross-Sectional CLINI-AEDV Study. Actas Dermosifiliogr. 2023 Nov 3:S0001-7310(23)00871-2. English, Spanish. doi: 10.1016/j.ad.2023.10.037. Epub ahead of print. PMID: 37923079.
8. Sánchez-Díaz M, Flórez Á, Ara-Martín M, Arias-Santiago S, Botella-Estrada R, Cañueto J, Carretero-Hernández G, Coto-Segura P, de Eusebio-Murillo E, García- Latasa de Araníbar FJ, García-Patos Briones V, Gardeazabal García J, Gómez- Fernández C, Hernández-Ostiz S, Izu Belloso R, López-Ávila A, Manchado López P,Martín-Santiago A, Martinez de Espronceda Ezquerro I, Mateu-Puchades A,Mercader-García P, Notario Rosa J, Palacio Aller L, Pérez-Hortet C, Quintana-Castanedo L, Rivera R, Rocamora Duran V, Rodríguez-Nevado IM, Ruiz-Villaverde R,Suárez J, Trasobares-Marugán L, Vizán-de Uña C, Yanguas I, Zulaica-Garate A,García-Doval I, Descalzo MÁ, Grau-Pérez M, Carrascosa-Carrillo JM. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study. Actas Dermosifiliogr. 2023 Oct 26:S0001-7310(23)00847-5. English, Spanish. doi: 10.1016/j.ad.2023.10.016. Epub ahead of print. PMID: 37890617.
9. Navarro-Triviño FJ, Galán-Gutiérrez M, Hita JC, Ruiz-Villaverde R, Domínguez-Cruz J, Pereyra-Rodríguez JJ. Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up. Dermatitis. 2023 Oct 26. doi: 10.1089/derm.2023.0220. Epub ahead of print. PMID: 37883648.
10. Prados-Carmona A, Ruiz-Villaverde R, Navarro-Triviño FJ. Is roflumilast a feasible alternative for the treatment of mucocutaneous lichen? J Dtsch Dermatol Ges. 2023 Dec;21(12):1554-1556. doi: 10.1111/ddg.15204. Epub 2023 Oct 15. PMID: 37840381.
11. Prados-Carmona A, Prados-Carmona JJ, Ruiz-Villaverde R, Navarro-Triviño FJ. Multiple minute digitate hyperkeratosis: 10 years from Caccetta's algorithm. A case report and narrative review. J Dtsch Dermatol Ges. 2023 Dec;21(12):1447-1454. doi: 10.1111/ddg.15186. Epub 2023 Oct 15. PMID: 37840359.
12. Prados-Carmona A, Ruiz-Villaverde R, Navarro-Triviño FJ. Could baricitinib be a safe and effective therapeutic alternative for incoercible pruritus in patients with dermatitis herpetiformis? Int J Dermatol. 2023 Oct 11. doi: 10.1111/ijd.16878. Epub ahead of print. PMID: 37818765.
13. Llamas-Velasco M, Fraga J, Rodríguez-Villa Lario A, Catalá A, Pérez-González YC, Galván C, Ruiz-Villaverde R, Sánchez-Pérez J, Wiesner T, Metze D. A Series of 69 COVID-related Dermatoses With Biopsy, Immunohistochemistry With Anti-spike 3, in situ Hybridization and PCR: A Critical Reappraisal of Viral Involvement in COVID-19 Skin Lesions. Actas Dermosifiliogr. 2023 Oct;114(9):T747-T754. English, Spanish. doi: 10.1016/j.ad.2023.05.031. Epub 2023 Jul 27. PMID: 37516249.
14. Couselo-Rodríguez C, Batalla A, Carrascosa JM, Chicharro P, González-Quesada A, de la Cueva P, Giménez-Arnau AM, Gilaberte Y, Rodríguez-Serna M, Montero- Vilchez T, Ruiz-Villaverde R, Elosua-González M, Silvestre-Salvador JF, Munera- Campos M, Sánchez-Pérez J, Carretero G, Mauleón-Fernández C, Curto-Barredo L,Ballano-Ruiz A, Botella-Estrada R, Arias-Santiago S, Navarro-Triviño FJ, Roustan-Gullón G, Betlloch I, Del Alcázar E, Abalde-Pintos MT, Suárez-Perez J, García-Doval I, Descalzo MÁ, Flórez Á. Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP). Actas Dermosifiliogr. 2023 Jul 22:S0001-7310(23)00608-7. English, Spanish. doi: 10.1016/j.ad.2023.07.014. Epub ahead of print. PMID: 37482292.
15. Martínez de Victoria-Carazo J, García-Ceberino PM, de Salazar-González A, Faro-Míguez N, Fuentes-López A, Viñuela-González L, Palomares-Rodríguez J, Valero-Ubierna C, Ruíz-Villaverde R, García-García F, Hernández-Quero J, Ruíz- Sancho AL. Mpox Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak. AIDS Res Hum Retroviruses. 2023 Nov;39(11):604-609. doi: 10.1089/AID.2023.0016. Epub 2023 Aug 11. PMID: 37450341.
16. Castellanos-Gonzalez M, Bris BB, Marsol IB, Campos MM, Ruiz-Villaverde R, Llorente CP, Nuno-Gonzalez A, Sánchez JT, Mur EC, García RG, Alonso AB, Español GA, García YH, Schmidt JMS, Sánchez MA, Crespo ER, Alonso ELH, Gallo-Pineda G, Izquierdo JAA, Varillas-Delgado D. [Prädiktive Faktoren für Anti-MDA5-Antikörper bei Patienten mit Dermatomyositis: eine retrospektive multizentrische Studie]. J Dtsch Dermatol Ges. 2023 Jul;21(7):741-750. German. doi: 10.1111/ddg.15089_g. PMID: 37427730.
17. Navarro-Triviño FJ, Prados-Carmona A, Aguilera J, de Gálvez MV, Ruiz- Villaverde R. [Behandlung der refraktären solaren Urtikaria: Könnte Dupilumab die derzeitige Lücke schließen?]. J Dtsch Dermatol Ges. 2023 Jun;21(6):652-654. German. doi: 10.1111/ddg.15025_g. PMID: 37338841.
18. Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz- Villaverde R. Updated Review on Treatment of Atopic Dermatitis. J Investig Allergol Clin Immunol. 2023 Jun;33(3):158-167. doi: 10.18176/jiaci.0906. PMID: 37318771.
19. Llamas-Molina JM, Velasco-Amador JP, De La Torre-Gomar FJ, Carrero-Castaño A, Ruiz-Villaverde R. Localized Cutaneous Nodular Amyloidosis in a Patient with Sjögren's Syndrome. Int J Mol Sci. 2023 May 28;24(11):9409. doi: 10.3390/ijms24119409. PMID: 37298361; PMCID: PMC10253770.
20. Navarro-Triviño F, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Ruiz-Villaverde R, Pereyra-Rodriguez JJ, Armario-Hita JC. Upadacitinib for moderate to severe atopic dermatitis. Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17. PMID: 37194577.
21. Velasco-Amador JP, Prados-Carmona A, Ruiz-Villaverde R. Dermatite radique associée au traitement de l’hépatocarcinome. CMAJ. 2023 May 8;195(18):E662-E663. French. doi: 10.1503/cmaj.221122-f. PMID: 37156558; PMCID: PMC10166621.
22. Gil-Villalba A, Moyano-Bueno D, Ruiz-Villaverde R. Subcutaneous Nodules and Eyelid Erythema in a Patient With Pulmonary Involvement. Actas Dermosifiliogr. 2023 Sep;114(8):731-732. English, Spanish. doi: 10.1016/j.ad.2022.07.035. Epub 2023 May 5. PMID: 37150248.
23. Llamas-Molina JM, Velasco-Amador JP, De la Torre-Gomar FJ, Carrero-Castaño A, Ruiz-Villaverde R. Localized Cutaneous Nodular Amyloidosis: A Specific Cutaneous Manifestation of Sjögren's Syndrome. Int J Mol Sci. 2023 Apr 17;24(8):7378. doi: 10.3390/ijms24087378. PMID: 37108553; PMCID: PMC10139233.
24. Pereyra-Rodríguez JJ, Herranz P, Ruiz-Villaverde R, Elosua-González M, Galán-Gutiérrez M, Figueras-Nart I, Miquel J, de la Cueva P, Serra-Baldrich E, Munera-Campos M, Melé-Ninot G, Expósito-Serrano V, Perez B, Serrano A, Ortiz de Frutos JF, Armario-Hita JC. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results. Clin Exp Dermatol. 2023 Aug 25;48(9):991-997. doi: 10.1093/ced/llad153. PMID: 37098171.
25. Prados-Carmona A, Cebolla-Verdugo M, Ruiz-Villaverde R. Sudden erythematous cutaneous eruption. Eur J Intern Med. 2023 May;111:115-116. doi: 10.1016/j.ejim.2023.03.007. Epub 2023 Mar 11. PMID: 36907783.
26. Perez-López I, Ruiz-Villaverde R. Long-Standing Lymphocutaneous Sporotrichosis. Sultan Qaboos Univ Med J. 2023 Feb;23(1):129-130. doi: 10.18295/squmj.8.2022.048. Epub 2023 Feb 23. PMID: 36865423; PMCID: PMC9974022.
27. Martín-Enguix D, Ruiz-Villaverde R, Galán-Gutiérrez M, Cabrerizo-Carvajal AM. Asociación entre penfigoide ampolloso y los inhibidores de la dipeptidil peptidasa-4, e impacto de su retirada [Association between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors and impact of their withdrawal]. Aten Primaria. 2023 Apr;55(4):102586. Spanish. doi: 10.1016/j.aprim.2023.102586. Epub 2023 Feb 24. PMID: 36842360; PMCID: PMC9974366.
28. Salgado-Boquete L, Arias-Santiago S, Belinchón-Romero I, de la Cuadra-Grande A, de la Cueva P, Gilaberte Y, Notario J, Rivera-Díaz R, Ruiz-Villaverde R, Carrascosa JM; Grupo Multidisciplinar y Grupo de Consenso. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study. Actas Dermosifiliogr. 2023 Nov-Dec;114(10):865-883. English, Spanish. doi: 10.1016/j.ad.2023.02.002. Epub 2023 Feb 15. PMID: 36796538.
29. Velasco-Amador JP, Prados-Carmona A, Ruiz-Villaverde R. Radiation dermatitis in a patient treated for hepatocarcinoma. CMAJ. 2023 Jan 23;195(3):E122. doi: 10.1503/cmaj.221122. PMID: 36690366; PMCID: PMC9876591.
30. Pegalajar-García MD, Pérez-López I, Gil-Villalba A, Cabrerizo-Carvajal AM, Ruiz Villaverde R. Lesión en el pene, más allá de lo venéreo [Penile lesion, beyond the venereal pathology]. Semergen. 2023 Jan-Feb;49(1):101824. Spanish. doi: 10.1016/j.semerg.2022.101824. Epub 2022 Dec 29. PMID: 36586185.
31. Gil Villalba A, Pegalajar García MD, Moyano Bueno D, Ruiz Villaverde R. Ampollas hemorrágicas en mucosa oral en puérpera [Hemorrhagic blisters in the oral cavity in a post-partum women]. Semergen. 2023 May-Jun;49(4):101905. Spanish. doi: 10.1016/j.semerg.2022.101905. Epub 2022 Dec 26. PMID: 36577265.
32. Velasco-Amador JP, Prados-Carmona A, Ruiz-Villaverde R. RF - Resistance to Permethrin in Scabies Treatment: Does It Really Exist? Actas Dermosifiliogr. 2023 May;114(5):433-434. English, Spanish. doi: 10.1016/j.ad.2022.05.036. Epub 2022 Dec 22. PMID: 36567030.
33. Velasco-Amador JP, Moreno-Suárez F, Ruiz-Villaverde R. Fluoroscopy-Induced Radiation Dermatitis. Actas Dermosifiliogr. 2023 Nov-Dec;114(10):912-913. English, Spanish. doi: 10.1016/j.ad.2022.09.017. Epub 2022 Nov 9. PMID: 36370832.
34. Navarro-Triviño FJ, Ruiz-Villaverde R. Lichenoid drug eruption induced by pravastatin; it is possible to prescribe other statins? An Bras Dermatol. 2023 Jan-Feb;98(1):116-117. doi: 10.1016/j.abd.2021.02.013. Epub 2022 Nov 1. PMID: 36333170; PMCID: PMC9837629.
35. Prados-Carmona A, Prados-Carmona JJ, Gálvez-Moreno M, Ruiz-Villaverde R. Are cyclosporine eye drops a suitable treatment in ocular rosacea? J Dermatolog Treat. 2023 Dec;34(1):2135964. doi: 10.1080/09546634.2022.2135964. Epub 2022 Oct 19. PMID: 36226904.
36. Martín Enguix D, Gil-Villalba A, Ruiz-Villaverde R. Aparición simultánea de granulomas en diferentes tatuajes: una forma inusual de sarcoidosis de las cicatrices [Simultaneous appearance of granulomas in different tattoos: An unusual form of scar sarcoidosis]. Semergen. 2023 Mar;49(2):101842. Spanish. doi: 10.1016/j.semerg.2022.101842. Epub 2022 Oct 6. PMID: 36209723.
37. Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC. Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. Int J Dermatol. 2023 Mar;62(3):e159-e161. doi: 10.1111/ijd.16399. Epub 2022 Aug 10. PMID: 35948826.
38. Ródenas-Herranz T, Linares-González L, Ruiz-Villaverde R. Long-Standing Gouty Panniculitis. Actas Dermosifiliogr. 2023 Jun;114(6):545. English, Spanish. doi: 10.1016/j.ad.2022.02.031. Epub 2022 Jun 23. PMID: 35753363.
39. De la Torre Gomar FJ, Gimeno Castillo J. Un arcoíris entre las colinas [A rainbow among the hills]. Semergen. 2023 Nov 3;50(2):102091. Spanish. doi: 10.1016/j.semerg.2023.102091. Epub ahead of print. PMID: 37925999.
40. Prados-Carmona A, De la Torre Gomar FJ. Acquired Reactive Perforating Collagenosis. N Engl J Med. 2023 Nov 2;389(18):e37. doi: 10.1056/NEJMicm2301877. PMID: 37913508.
41. Gimeno Castillo J, De la Torre Gomar FJ, Menéndez Parrón A, Martínez de Lagrán Álvarez de Arcaya Z. Oral roflumilast as a therapeutic option for psoriasis, what role does it have? Case report and literature review. J Dermatolog Treat. 2023 Dec;34(1):2240456. doi: 10.1080/09546634.2023.2240456. PMID: 37491902.
42. Llamas-Molina JM, Ayén-Rodríguez Á, De la Torre-Gomar FJ. RF - Carvedilol and Its Applications in Dermatology. Actas Dermosifiliogr. 2023 Nov- Dec;114(10):896-898. English, Spanish. doi: 10.1016/j.ad.2023.05.026. Epub 2023 Jun 23. PMID: 37356542.
43. Gimeno Castillo J, de la Torre Gomar FJ. RF- Topical Cholesterol and Statin Formulation to Treat Porokeratosis. Actas Dermosifiliogr. 2023 Jun;114(6):533-535. English, Spanish. doi: 10.1016/j.ad.2022.06.025. Epub 2023 Mar 15. PMID: 36925100.
44. de la Torre Gomar FJ, Gimeno Castillo J, Rosés Gibert P, Iglesias Martínez E, Martínez González MI. Silicone-induced granulomas successfully treated with adalimumab. J Dermatolog Treat. 2023 Dec;34(1):2174786. doi: 10.1080/09546634.2023.2174786. PMID: 36715364.
45. Sánchez-García V, Navarro-Triviño FJ, Silvestre JF. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1426-e1429. doi: 10.1111/jdv.19348. Epub 2023 Jul 21. PMID: 37458506.
46. Schneller-Pavelescu L, Vergara-de Caso E, Martorell A, Romaní J, Lázaro M, Vilarrasa E, Díaz-Ley B, Vázquez-Osorio I, Segura Palacios JM, Azaña JM, González-López MA, Cañueto J, Molina-Leyva A, Leiva-Salinas M, Navarro-Triviño FJ, Sánchez-Payá J, Pascual JC. Reply to: "Comment on 'Interruption of oral clindamycin plus rifampicin therapy in patients with hidradenitis suppurativa: An observational study to assess prevalence and causes'". J Am Acad Dermatol. 2023 May;88(5):e271-e272. doi: 10.1016/j.jaad.2019.03.006. Epub 2019 Mar 11. PMID: 30872153.

 

Unidad de Laserterapia

 

1. Gil-Villalba A, Ayen-Rodriguez A, Naranjo-Diaz MJ, Ruiz-Villaverde R. Laser Therapy for Vulvar Lichen Sclerosus, a Systematic Review. Life (Basel). 2023 Oct 31;13(11):2146. doi: 10.3390/life13112146. PMID: 38004286; PMCID: PMC10672171.

 

Unidad de Dermatologia Pediátrica

 

2. Pérez-López I, Herrera García JD, Ayén Rodríguez A, Ruiz-Villaverde R. Bilateral Temporal Arachnoid Cysts Associated With Phakomatosis Cesioflammea. Actas Dermosifiliogr. 2023 Jul 22:S0001-7310(23)00610-5. English, Spanish. doi: 10.1016/j.ad.2022.10.052. Epub ahead of print. PMID: 37482295.
3. Pérez-López I, Garrido-Colmenero C, Ruiz-Villaverde R. Recurrent Rash on the Left Side of the Face: A Diagnostic Challenge. Actas Dermosifiliogr. 2023 Jul 22:S0001-7310(23)00606-3. English, Spanish. doi: 10.1016/j.ad.2023.02.027. Epub ahead of print. PMID: 37482289.

 

Unidad de Melanoma y Oncologia Cutánea

 

1. Ruiz-Villaverde R, Herrera-Acosta E, Ruiz de Casas A, Villegas-Romero IM, Moreno-Suárez FG, Vílchez-Márquez F, Galán-Gutiérrez M, Vázquez-Bayo MC, Cases- Mérida S, Almazán-Fernández FM. Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice. J Clin Med. 2023 Aug 29;12(17):5631. doi: 10.3390/jcm12175631. PMID: 37685698; PMCID: PMC10488851.
2. Ayén-Rodríguez A, Linares-González L, Llamas-Segura C, Almazán-Fernández FM, Ruiz-Villaverde R. Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center. Int J Environ Res Public Health. 2023 May 15;20(10):5824. doi: 10.3390/ijerph20105824. PMID: 37239551; PMCID: PMC10218270.
3. Prados-Carmona A, Llamas-Molina JM, Velasco-Amador P, Ruiz-Villaverde R, Ruiz-Carrascosa JC. High-risk squamous cell carcinoma, a surgical challenge: the other face of the SARS-CoV-2 pandemic. J Dermatolog Treat. 2023 Dec;34(1):2192841. doi: 10.1080/09546634.2023.2192841. PMID: 36927214.

 

Unidad de Fototerapia

 

1. Prados-Carmona A, Ruiz-Villaverde R, de Gálvez Aranda MV, Arjona JA, Navarro-Triviño FJ. Successful treatment of chronic actinic dermatitis with alitretinoin: Should retinoids be included in the therapeutical arsenal? Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):532-534. doi: 10.1111/phpp.12888. Epub 2023 May 18. PMID: 37199021.
2. Navarro-Triviño FJ, Prados-Carmona A, Aguilera J, de Gálvez MV, Ruiz- Villaverde R. Treatment of refractory solar urticaria: could dupilumab fill the current gap? J Dtsch Dermatol Ges. 2023 Jun;21(6):652-653. doi: 10.1111/ddg.15025. Epub 2023 May 8. PMID: 37154304.
3. Pegalajar-García MD, De la Torre-Gomar FJ, Ruiz-Villaverde R. Is the UVA1 phototherapy an effective option in keloids treatment? Photodermatol Photoimmunol Photomed. 2023 Mar;39(2):162-165. doi: 10.1111/phpp.12856. Epub 2023 Jan 19. PMID: 36596276.
4. Velasco-Amador JP, Linares-Gonzalez L, De la Torre-Gomar FJ. Efficacy and Satisfaction of Low Doses UVA1 Phototherapy: A Spanish Experience from a Single Centre. Life (Basel). 2023 Feb 28;13(3):669. doi: 10.3390/life13030669. PMID: 36983825; PMCID: PMC10059657.
5. de Gálvez MV, Aguilera J, Navarrete-de Gálvez E, Sánchez-Roldán C, Navarro- Triviño FJ, Herrera-Ceballos E. An unusual case of solar urticaria exacerbated by clothing: Confirmation through phototesting. Photodermatol Photoimmunol Photomed. 2023 Jul;39(4):403-406. doi: 10.1111/phpp.12845. Epub 2022 Dec 7. PMID: 36398940.

 

Unidad de Inmunoalergia

 

1. Navarro-Triviño FJ, Prados-Carmona Á, Velasco-Amador JP, Ruiz-Villaverde R. Bullous Allergic Contact Dermatitis Caused by Potassium Dichromate. Sultan Qaboos Univ Med J. 2023 Feb;23(1):127-128. doi: 10.18295/squmj.5.2022.037. Epub 2023 Feb 23. PMID: 36865427; PMCID: PMC9974029.
2. Navarro-Triviño FJ, Prados-Carmona Á, Linares-González L, Velasco-Amador JP, Ruiz-Villaverde R. Occupational protein contact dermatitis caused by lettuce and overlap allergic contact dermatitis by parthenolide: A diagnostic approach. Australas J Dermatol. 2023 May;64(2):e175-e177. doi: 10.1111/ajd.13992. Epub 2023 Feb 3. PMID: 36737672.
3. Llamas-Molina JM, Prados-Carmona Á, Velasco-Amador P, Ruiz-Villaverde R, Navarro-Triviño FJ. Allergic contact dermatitis caused by herbicide containing glyphosate-isopropylamine salt. Contact Dermatitis. 2023 Mar;88(3):230-232. doi: 10.1111/cod.14252. Epub 2022 Nov 28. PMID: 36416721.
4. Ayén-Rodríguez A, Llamas-Molina JM, Gálvez-Moreno M, Ruiz-Villaverde R. Cold urticarial vasculitis successfully treated with omalizumab. Int J Dermatol. 2023 Feb;62(2):e77-e78. doi: 10.1111/ijd.16133. Epub 2022 Feb 15. PMID: 35167707.
5. Pegalajar-García MD, Cebolla-Verdugo M, Prados-Carmona Á, Llamas-Segura C, Navarro-Triviño FJ. Systemic allergic dermatitis to cobalt present in cyanocobalamin supplementation. Contact Dermatitis. 2023 Sep;89(3):203-205. doi: 10.1111/cod.14362. Epub 2023 Jun 8. PMID: 37290457.
6. Velasco-Amador JP, Prados-Carmona Á, Navarro-Triviño FJ. Contact urticaria syndrome caused by alpha-lipoic acid in a master formula for vulvar lichen sclerosus. Contact Dermatitis. 2023 Aug;89(2):136-137. doi: 10.1111/cod.14353. Epub 2023 May 30. PMID: 37254612.
7. Navarro-Triviño FJ. Pruritus in Dermatology: Part 2 - Diseases and Their Treatment. Actas Dermosifiliogr. 2023 Jul-Aug;114(7):613-626. English, Spanish. doi: 10.1016/j.ad.2023.03.004. Epub 2023 Mar 31. PMID: 37003460.
8. Navarro-Triviño FJ. Pruritus in Dermatology: Part 1 - General Concepts and Pruritogens. Actas Dermosifiliogr. 2023 Jun;114(6):512-522. English, Spanish. doi: 10.1016/j.ad.2023.03.003. Epub 2023 Mar 23. PMID: 36965771.

 

Unidad de Psoriasis

 

1. Ruiz-Villaverde R, Galan-Gutierrez M, Armario-Hita JC, Rodriguez-Fernandez- Freire L. Efficacy and Pharmacoeconomic Analysis in Real Clinical Practice Conditions of Patients with Plaque Psoriasis Treated with Guselkumab: A Retrospective Multicenter Study. Actas Dermosifiliogr. 2023 Nov 2:S0001-7310(23)00855-4. English, Spanish. doi: 10.1016/j.ad.2023.10.023. Epub ahead of print. PMID: 37923077.
2. Jiménez Gómez N, González-Cantero Á, Ruiz-Villaverde R, Llamas-Velasco M, de la Cueva Dobao P, Rivera Díaz R, Martínez Lorenzo E, Alonso Pacheco ML, Baniandrés Rodríguez O, Mollet Sánchez J, Pitarch Bort G, Izu Belloso RM, Jaén Olasolo P. [Translated article] Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study. Actas Dermosifiliogr. 2023 Nov 3:S0001-7310(23)00863-3. English, Spanish. doi: 10.1016/j.ad.2023.10.030. Epub ahead of print. PMID: 37923069.
3. Prados-Carmona A, Ruiz-Villaverde R, Ruiz-Carrascosa JC. Rupioid psoriasis. Semergen. 2023 Oct;49(7):102061. doi: 10.1016/j.semerg.2023.102061. Epub 2023 Sep 8. PMID: 37690349.
4. Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González- Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, Llamas-Velasco M; Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2517-2525. doi: 10.1111/jdv.19468. Epub 2023 Sep 1. PMID: 37625815.
5. Sahuquillo-Torralba A, Hospital-Gil M, Vilarrasa-Rull E, Llamas-Velasco M, Rivera R, Carrascosa JM, de la Cueva-Dovao P, Armesto-Santos S, Ruíz-Villaverde R, Velasco-Pastor M, Magdaleno-Tapial J, Yanguas-Bayona JI, Ribera-Pibernat M, Salgado-Boquete L, Herranz-Pinto P, Romero-Mate A, Martínez-Lorenzo E, López-Estebaranz JL, Ballescá-López F, Botella-Estrada R. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population. Australas J Dermatol. 2023 Nov;64(4):e317-e326. doi: 10.1111/ajd.14130. Epub 2023 Jul 12. PMID: 37435962.
6. Ruiz-Villaverde R, Galán-Gutiérrez M, Llamas-Velasco M, Salgado-Boquete L, Puig L, de la Cueva P, Carrascosa JM; en representación del Grupo Español de Psoriasis (GPs). Updated Position of the Spanish Psoriasis Group (GPs) on the Use of Biosimilar Drugs in Moderate to Severe Psoriasis. Actas Dermosifiliogr. 2023 Jun;114(6):494-501. English, Spanish. doi: 10.1016/j.ad.2023.02.016. Epub 2023 Mar 10. PMID: 36906260.
7. Galan-Gutierrez M, Font-Ugalde P, Padilla L, Hernandez-Montoya C, Godoy D, Armario-Hita JC, Ruiz-Villaverde R. Brodalumab: Efficacy, safety, and survival in mid-term (52 weeks) on real clinical practice in Andalucia, Spain. Int J Dermatol. 2023 May;62(5):700-706. doi: 10.1111/ijd.16527. Epub 2022 Dec 10. PMID: 36495585.
8. Mataix J, García L, Belinchón I, Ruiz Carrascosa JC, de la Cueva P, Carrascosa JM. Moderate to Severe Psoriasis in Older Adults: Recommendations on Management from the Psoriasis Working Group of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermosifiliogr. 2023 Oct;114(9):802-811. English, Spanish. doi: 10.1016/j.ad.2023.05.016. Epub 2023 May 25. PMID: 37244396.
9. Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC. Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. Int J Dermatol. 2023 Mar;62(3):e159-e161. doi: 10.1111/ijd.16399. Epub 2022 Aug 10. PMID: 35948826.

 

Unidad de Tricología

 

1. Lobato-Berezo A, Escolà-Rodríguez A, Courtney A, Chim I, Ruiz-Villaverde R, Imbernón-Moya A, Velasco-Tamariz V, Vañó-Galván S, Gil-Redondo R, Del Boz J, Garnacho Saucedo G, Starace M, Saceda-Corralo D, Quadrelli F, Piraccini BM, Pujol RM. Acne keloidalis nuchae: An international multicentric review of 79 patients. J Eur Acad Dermatol Venereol. 2023 Nov 1. doi: 10.1111/jdv.19609. Epub ahead of print. PMID: 37909243.
2. Carmona-Rodríguez M, Moro-Bolado F, Romero-Aguilera G, Ruiz-Villaverde R, Carriel V. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344. doi: 10.3390/life13061344. PMID: 37374126; PMCID: PMC10300830.
3. Porriño-Bustamante ML, Montero-Vílchez T, Fernández-Pugnaire MA, Arias-Santiago S. Frontal Fibrosing Alopecia Quality of Life Index: A Validated Disease-Specific Questionnaire Involving Women. J Clin Med. 2023 Jan 20;12(3):824. doi: 10.3390/jcm12030824. PMID: 36769473; PMCID: PMC9917648.
4. Pegalajar-García MD, Gil-Villalba A, de la Torre-Gomar FJ. RF - Bicalutamide: An Emergent Treatment Option in Trichology. Actas Dermosifiliogr. 2023 Oct;114(9):812-815. English, Spanish. doi: 10.1016/j.ad.2022.08.034. Epub 2023 Jun 19. PMID: 37343820.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ESTUDIOS OBSERVACIONALES

 

Unidad de Terapia Fotodinámica

 

Terapia Fotodinámica convencional vs Terapia Fotodinámica Luz de Día + Terapia Fotodinámica Convencional

Promotor: Servicio de Dermatología. Hospital Universitario Clínico San Cecilio

FEA. Soledad Saénz Guirado

 

Publicaciones:

 

Sáenz-Guirado S, Cuenca-Barrales C, Vega-Castillo J, Linares-Gonzalez L, Ródenas-Herranz T, Molina-Leyva A, Ruiz-Villaverde R. Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study. Photodermatol Photoimmunol Photomed. 2021

 

Unidad de Melanomas/Oncología cutánea

 

Conservative nodal surgery (node-picking) of patients with stage III melanoma with low-burden of nodal disease (MELCONSURG MULTICENTRE COHORT)

Promotor: Hospital Universitario Virgen Macarena.

IP David Moreno Ramirez

FEA. Francisco Almazan Fernandez y Ricardo Ruiz Villaverde

 

Caracterización de las propiedades mecánicas in vivo de la piel normal frente a la sospechosa de tumores benignos y de melanoma y carcinoma escamoso y basocelular. ELASTOME

IP: José Luis Martín Rodríguez/Inas H.Faris

COLABORADORES: Aurelio Martín Castro, Ricardo Ruiz Villaverde, Hirad Shamimi Noori, Jose M. Cortés, Jorge Torres, Guillermo Rus

 

Abordaje de la salud oral y la calidad de vida en supervivientes de cáncer de cabeza y cuello mediante terapia de fotobiomodulación complementada con un sistema de m-health. estudio l3axer.

Promotor: UGR. Grupo Cuidate

IP: Noelia Galiano Castillo

Colaborador: Ricardo Ruiz Villaverde

 

Estudio de microARNs circulantes y parámetros de estrés oxidativo e inflamación como  biomarcadores en el carcinoma basocelular

IP: Germaine Escamez

Promotor: UGR. MP17. Comunicación intracelular

Colaborador: Ricardo Ruiz Villaverde

 

 

 

 

 

 

 

 

 

 

 

 

 

Dermatología General

 

Generación de cohortes y caracterización multiómica del Síndrome de Sjögren y la Dermatitis Atópica

Promotor. Jose M Carrascosa. Hospital Germans Trias i Pujol

Colaborador. Ricardo Ruiz Villaverde

 

Caracterización histología y molecular de la matriz extracelular en la AAF. Estudio prospectivo, abierto, no controlado

Promotor: Servicio de Dermatología. Hospital Universitario Clínico San Cecilio

FEA: Ricardo Ruiz Villaverde y Francisco J Navarro Triviño

En activo

 

Publicaciones: Carmona-Rodríguez M, Moro-Bolado F, Romero-Aguilera G, Ruiz-Villaverde R, Carriel V. Frontal Fibrosing Alopecia: An Observational Single-Center Study of 306 Cases. Life (Basel). 2023 Jun 8;13(6):1344. doi: 10.3390/life13061344. PMID: 37374126; PMCID: PMC10300830.

 

A prospective observational study of adult patients receiving Dupixent for atopic dermatitis

Protocol Number: OBS15990 / GLOBOSTAD

Investigador principal: Ricardo Ruiz Villaverde

En activo

 

Elaboración de un atlas celular diferenciado por sexo de tejido cutáneo en pacientes con esclerosis sistémica mediante secuenciación del transcriptoma de célula única.

Investigador Principal: Dra. Marialbert Acosta Herrera   

Hospital/Centro: Instituto de Investigación Biosanitaria de Granada

Colaborador: Ricardo Ruiz Villaverde

 

Estudio observacional para identificar las características clínicas, metodología diagnóstica, abordaje terapéutico y la comorbilidad vinculada al prurigo nodular en la práctica clínica

Promotor: Galderma

GAL-PN-2022-01

Investigador principal: Ricardo Ruiz Villaverde

En activo

 

Perspectiva del paciente respecto a la dermatitis atópica en España, estudio transversal y  ulticéntrico (3p-stADy)

Promotor: Abbvie

H24-077

Investigador principal: Ricardo Ruiz Villaverde

En activo

 

Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)

Promotor: Abbvie

Codigo: Protocolo P20-441

Investigador principal: José Carlos Ruiz Carrascosa

En Activo

 

Tralokinumab ReAl world Clinical usE An observational cohort study of atopic dermatitis patients prescribed tralokinumab

Promotor: Leo Pharma

Codigo: LEO Pharma_TRACE_NIS-TRALO-2213

Investigador principal: Ricardo Ruiz Villaverde

En Activo

 

A 24-Month Prospective Observational Cohort Study Evaluating Oral Systemic Therapies in the Management of Adult Patients with Atopic Dermatitis in REAL-World Practice (AD-REAL)

Promotor: Lilly

Codigo: Protocol I4V-MC-B026

Investigador principal: Ricardo Ruiz Villaverde

En Activo

 

 

Unidad de Psoriasis

 

A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study

Promotor: Almirall

Codigo: M-14745-47

Investigador principal: José Carlos Ruiz Carrascosa

En activo

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ENSAYOS CLINICOS ACTIVOS

 

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT03569293

Co-investigadores: Ricardo Ruiz Villaverde

Carácter: Europeo

Laboratorio responsable: Abbvie SA

Investigador principal Local: Jose C Ruiz Carrascosa

Iniciado en 2019, en curso (n=6, 2 en activo)

Psoriasis Longitudinal Assessment and Registry (PSOLAR). Registry C0168Z03. A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Código del protocolo: ClinicalTrials.gov Identifier: NCT00508547

Promotor: Janssen Scientific Affairs, LLC

Investigador principal: Jose Carlos Ruiz Carrascosa

Iniciado en 2020  (n=8)

 

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid Protocol Number: ARGX-113-2009 Version Number: 1.0 (Original)

Promotor: Argenx BV

Investigador Principal: David Moyano Bueno

Iniciado en 2022 (n=3)

 

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD+)

Number: ARGX-113-2010. ClinicalTrials.gov Identifier: NCT05681481

Promotor: Argenx BV

Investigador Principal: David Moyano Bueno

Iniciado en 2022 (n=3)

 

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigo Protocol Number: ARGX-113-1904 Version Number: 1.0 (Original) Compound: Efgartigimod (ARGX-113) Brief Title: A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigo Study Phase: 2/3

Promotor: Argenx BV

Investigador Principal: David Moyano Bueno

Iniciado en 2023

 

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus). Number: ARGX-113-1905

Promotor: Argenx BV

Investigador Principal: David Moyano Bueno

Iniciado en 2023

 

Protocol Title: A Phase 4, Multi-centre, Randomized, Evaluator[1]blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients with Actinic Keratosis on the Face or Scalp.

Clinical Trial Code: M-14789-41

Sponsor Name: Almirall, S.A.

Investigador principal: Ricardo Ruiz Villaverde

Iniciado en 2022 (n=8)

 

LP0133-1426 “A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in adolescents 12-17 years of age with moderate to severe chronic hand eczema”  

Promotor: Leo Pharma

Investigador Principal: Francisco J Navarro Triviño

Iniciado en 2022 (n=3)

 

A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 2 to <12 years) with moderate-to-severe atopic dermatitis. LP0162-1335

Promotor: Leo Pharma

Investigador Principal: Ricardo Ruiz Villaverde

Iniciado en 2023

 

Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.

Protocol Number: 1368-0098

Promotor: Boehringer-ingelheim.com

Investigador Principal: Ricardo Ruiz Villaverde

Iniciado en 2023

 

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. ClinicalTrials.gov Identifier: NCT06143878

Promotor: Janssen Scientific Affairs, LLC

Investigador principal: Jose Carlos Ruiz Carrascosa

Iniciado en 2023

 

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet) (ICONIC-TOTAL). ClinicalTrials.gov Identifier: NCT06095102

Promotor: Janssen Scientific Affairs, LLC

Investigador principal: Jose Carlos Ruiz Carrascosa

Iniciado en 2023

 

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND). ClinicalTrials.gov Identifier: NCT05958407

Promotor: Leo Pharma

Investigador Principal: Francisco Navarro Triviño

Iniciado en 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

zar a editar el contenido